Início › Câncer de Esôfago › Pensilvânia › Pittsburgh
Ensaios clínicos de Câncer de Esôfago em Pittsburgh, PA
15 estudos para Câncer de Esôfago estão buscando participantes em locais em Pittsburgh e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
RecrutandoFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 4904), Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Recrutando
- UPMC Hillman Cancer Center, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RecrutandoFase 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecrutandoFase 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
RecrutandoFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RecrutandoFase 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RecrutandoFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 8904), Pittsburgh
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
RecrutandoFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 6904), Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
RecrutandoFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
Recrutando
- UPMC Hillman Cancer Center, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RecrutandoFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Esophageal Cancer Risk Registry
RecrutandoEstudo observacional
- Department of Cardiothoracic Surgery, Pittsburgh
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
RecrutandoEstudo observacional
- University of Pittsburgh Medical Center - Department of Cardiothoracic Surgery, Pittsburgh
- UPMC - Hillman Cancer Center, Pittsburgh
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
RecrutandoEstudo observacional
- Allegheny Health Network, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
RecrutandoFase 1
- AHN West Penn Hospital, Pittsburgh
Ensaios de Câncer de Esôfago em outras cidades
- Houston, TX36 estudos
- Boston, MA23 estudos
- New York City, NY22 estudos
- Nashville, TN19 estudos
- St. Louis, MO17 estudos
- Los Angeles, CA15 estudos
- Baldwin Park, CA14 estudos
- Grand Rapids, MI14 estudos
- Philadelphia, PA13 estudos
- San Antonio, TX12 estudos
- Rochester, MN11 estudos
- Chicago, IL11 estudos
Outros estudos em Pittsburgh
- Câncer de Pulmão de Não Pequenas Células48 estudos
- Câncer (todos os tipos)41 estudos
- Câncer de Mama39 estudos
- Câncer Colorretal32 estudos
- Câncer Metastático31 estudos
- Melanoma31 estudos
- Câncer de Ovário30 estudos
- Câncer Endometrial23 estudos
- Câncer de Próstata23 estudos
- Câncer de Pulmão23 estudos
- Carcinoma de Células Escamosas de Cabeça e Pescoço22 estudos
- Acidente Vascular Cerebral22 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.